Anxiety disorders in young adult: Experience of treatment with maritupirdine

Introduction. Anxiety disorders are among the most common mental disorders in the world, having a significant impact on psychological health and social functioning, including adolescents and young adults. These disorders usually manifest themselves at the age of 10–24 years and lead to serious health problems.

Aim. To study the clinical features of anxiety disorders within generalized anxiety disorder (GAD), identify the leading manifestations and additional pantomimic, gestural and behavioral marker symptoms, and evaluate the effectiveness of the anxiolytic maritupirdine (Aviandr®) for the treatment of these conditions.

Materials and methods. 142 patients with diagnosed clinical-psychopathological and experimental-psychological methods of GAD were examined. Criteria for inclusion in the study: age 18–24 years, patient’s compliance with the criteria of GAD according to DSM-5. Exclusion criteria: the presence of a clinically relevant somatic or neurological disease, pregnancy or pregnancy planning (in women), taking psychotropic drugs during the month preceding inclusion in the study. The Mini-SMILE test, the Spielberger–Khanin test, and the Beck test were used. Patients were prescribed the anxiolytic Aviandr® 20 mg twice daily for 6 weeks.

Results. Among the examined young patients with GAD, 6 groups of GAD manifestations and a number of behavioral markers were identified. A statistically significant decrease in scores was noted in the domain of emotional manifestations, on the scales of mental manifestations and symptoms of stress, in the behavioral domain, in somatic manifestations. The largest relative decrease was found on the Beck scale, with situational anxiety in second place in sensitivity to Aviandr®, personal anxiety, and Mini-MIL scores decreased by more than a third.

Conclusion. Aviandr® had a positive effect in reducing the severity of GAD.

1. Su X. Influence of Social Media and Family Environment on Adolescent Anxiety Disorder. J Educ Humanit Soc Sci. 2023;22:207–213. https://doi.org/10.54097/ehss.v22i.12421.

2. Patton GC, Coffey C, Romaniuk H, Mackinnon A, Carlin JB, Degenhardt L et al. The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet. 2014;383(9926):1404–1411. http://doi.org/10.1016/s0140-6736(13)62116-9.

3. Konnopka A, König H. Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis. Pharmacoeconomics. 2020;38(1):25–37. https://doi.org/10.1007/s40273-019-00849-7.

4. Castaldelli-Maia JM, Bhugra D. Analysis of global prevalence of mental and substance use disorders within countries: focus on sociodemographic characteristics and income levels. Int Rev Psychiatry. 2022;34(1):6–15. https://doi.org/10.1080/09540261.2022.2040450.

5. Restar AJ, Jin H, Jarrett B, Adamson T, Baral SD, Howell S, Beckham SW. Characterising the impact of COVID-19 environment on mental health, gender affirming services and socioeconomic loss in a global sample of transgender and non-binary people: a structural equation modelling. BMJ Glob Health. 2021;6(3):e004424. https://doi.org/10.1136/bmjgh2020-004424.

6. Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021;397(10277):914–927. https://doi.org/10.1016/S0140-6736(21)00359-7.

7. Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM, Wittchen HU. Anxiety disorders. Nat Rev Dis Primers. 2017;3:17024. https://doi.org/10.1038/nrdp.2017.24.

8. Bie F, Yan X, Xing J, Wang L, Xu Y, Wang G et al. Rising global burden of anxiety disorders among adolescents and young adults: trends, risk factors, and the impact of socioeconomic disparities and COVID-19 from 1990 to 2021. Front Psychiatry. 2024;15:1489427. https://doi.org/10.3389/fpsyt.2024.1489427.

9. Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA, Ahbabi AA. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Curr Psychiatry. 2023;30(1):44. http://doi.org/10.1186/s43045-023-00315-3.

10. Goodwin RD, Weinberger AH, Kim JH, Wu M, Galea S. Trends in anxiety among adults in the United States, 2008–2018: Rapid increases among young adults. J Psychiatr Res. 2020;130:441–446. http://doi.org/10.1016/j.jpsychires.2020.08.014.

11. Love AS, Love R. Anxiety Disorders in Primary Care Settings. Nurs Clin North Am. 2019;54(4):473–493. https://doi.org/10.1016/j.cnur.2019.07.002.

12. Meuret AE, Tunnell N, Roque A. Anxiety Disorders and Medical Comorbidity: Treatment Implications. Adv Exp Med Biol. 2020;1191:237–261. https://doi.org/10.1007/978-981-32-9705-0_15.

13. DeGeorge KC, Grover M, Streeter GS. Generalized Anxiety Disorder and Panic Disorder in Adults. Am Fam Physician. 2022;106(2):157–164. Available at: https://pubmed.ncbi.nlm.nih.gov/35977134/.

14. DeMartini J, Patel G, Fancher TL. Generalized Anxiety Disorder. Ann Intern Med. 2019;170(7):ITC49–ITC64. https://doi.org/10.7326/AITC201904020.

15. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety disorders in older adults: a comprehensive review. Depress Anxiety. 2010;27(2):190–211. https://doi.org/10.1002/da.20653.

16. Craske MG, Kircanski K, Epstein A, Wittchen HU, Pine DS, Lewis-Fernández R et al. Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V. Depress Anxiety. 2010;27(2):93–112. https://doi.org/10.1002/da.20654.

17. Durazzo M, Gargiulo G, Pellicano R. Non-cardiac chest pain: a 2018 update. Minerva Cardioangiol. 2018;66(6):770–783. https://doi.org/10.23736/S0026-4725.18.04681-9.

18. Jafferany M, Khalid Z, McDonald KA, Shelley AJ. Psychological Aspects of Factitious Disorder. Prim Care Companion CNS Disord. 2018;20(1):17nr02229. https://doi.org/10.4088/PCC.17nr02229.

19. Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom. 2015;84(1):22–29. https://doi.org/10.1159/000367913.

20. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996. https://doi.org/10.1136/bmj.g1996.

21. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–335. https://doi.org/10.31887/dcns.2015.17.3/bbandelow.

22. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31. https://doi.org/10.1016/j.genhosppsych.2015.11.005.

23. Herr NR, Williams JW, Jr, Benjamin S, McDuffie J. Does this patient have generalized anxiety or panic disorder?: The Rational Clinical Examination systematic review. JAMA. 2014;312(1):78–84. https://doi.org/10.1001/jama.2014.5950.

24. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571–1575. https://doi.org/10.1176/ajp.154.11.1571.

25. Melchert TP, Halfond RW, Hamdi NR, Bufka LF, Hollon SD, Cuttler MJ. Evidence-based practice in psychology: Context, guidelines, and action. Am Psychol. 2024;79(6):824–837. https://doi.org/10.1037/amp0001253.

26. Society for Adolescent Health and Medicine. Young Adult Health and WellBeing: A Position Statement of the Society for Adolescent Health and Medicine. J Adolesc Health. 2017;60(6):758–759. https://doi.org/10.1016/j.jadohealth.2017.03.021.

27. Guaiana G, Meader N, Barbui C, Davies SJ, Furukawa TA, Imai H et al. Pharmacological treatments in panic disorder in adults: a network metaanalysis. Cochrane Database Syst Rev. 2023;(11):CD012729. https://doi.org/10.1002/14651858.cd012729.pub3.

28. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database Syst Rev. 2016;(4):CD011004. https://doi.org/10.1002/14651858.cd011004.pub2.

29. Taylor GM, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, Te Water Naudé R et al. Smoking cessation for improving mental health. Cochrane Database Syst Rev. 2021;(3):CD013522. https://doi.org/10.1002/14651858.cd013522.pub2.

30. Mishra AK, Varma AR. A Comprehensive Review of the Generalized Anxiety Disorder. Cureus. 2023;15(9):e46115. https://doi.org/10.7759/cureus.46115.

31. Chapdelaine A, Carrier JD, Fournier L, Duhoux A, Roberge P. Treatment adequacy for social anxiety disorder in primary care patients. PloS ONE. 2018;13(11):e0206357. https://doi.org/10.1371/journal.pone.0206357.

32. Bushnell GA, Rynn MA, Crystal S, Gerhard T, Olfson M. Simultaneous Benzodiazepine and SSRI Initiation in Young People With Anxiety Disorders. J Clin Psychiatry. 2021;82(6):20m13863. https://doi.org/10.4088/jcp.20m13863.

33. van Dis EAM, van Veen SC, Hagenaars MA, Batelaan NM, Bockting CLH, van den Heuvel RM et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Metaanalysis. JAMA Psychiatry. 2020;77(3):265–273. https://doi.org/10.1001/jamapsychiatry.2019.3986.

34. Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016;53(2):583–620. https://doi.org/10.3233/jad-151146.

35. Parfenov VA. Aviandr is a new original drug for treating anxiety. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(4):98–102. (In Russ.) https://doi.org/10.14412/2074-2711-2024-4-98-102.

36. Ivashchenko AA, Morozova MA, Vostokova NV, Beniashvily AG, Bukhanovskaya OA, Burminskiy DS et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study. J Psychiatr Res. 2021;143:436–444. https://doi.org/10.1016/j.jpsychires.2021.10.008.

37. Esipov AV, Samushiya MA, Ivolgin AF, Hommyatov MR, Kozachuk AYu, Elina IA et al. New opportunities for therapy of adjustment disorder in combat participants: results of a study on the domestic drug Aviandr. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2025;125(3):62–69. (In Russ.) https://doi.org/10.17116/jnevro202512503162.

38. Popova VB, Antonova EA, Hlyabova PM, Rodyukova IS, Alpenidze DN, Drozdova YuV et al. Efficacy and safety of Aviandr in the treatment of anxiety in patients with adjustment disorders after COVID-19. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2024;124(7):131–138. (In Russ.) https://doi.org/10.17116/jnevro2024124071131.